Abstract
G protein-coupled receptors (GPCRs) are major drug targets and are organized in dimeric/oligomeric complexes. These dimers may be composed of identical (homodimer) or different (heterodimer) receptors. GPCR dimerization provides new opportunities for drug design. Different strategies have been developed to specifically target GPCR dimers. Bivalent ligands, which are composed of two functional pharmacophores linked by a spacer, are among the most promising strategies. Due to the constitutive nature of GPCR dimers, bivalent ligands are expected in most cases to bind to and stabilize preexisting dimers rather then to promote ligand-induced dimerization. Most studies on GPCR dimerization were conducted so far in heterologous expression systems. Due the development of heterodimerspecific tools such as bivalent ligands, dimerization has now been confirmed for an increasing number of receptors in native tissues. In this review, we will discuss general considerations for the design and synthesis of bivalent ligands and present the functional in vitro and in vivo properties of reported bivalent ligands.
Keywords: Bivalent ligand, GPCR dimerization, drug design, spacer attachment point, spacer size, spacer chemical structure, heterodimers, GPCR oligomers
Current Drug Discovery Technologies
Title: Bivalent Ligands as Specific Pharmacological Tools for G Protein-Coupled Receptor Dimers
Volume: 5 Issue: 4
Author(s): Isabelle Berque-Bestel, Frank Lezoualc'h and Ralf Jockers
Affiliation:
Keywords: Bivalent ligand, GPCR dimerization, drug design, spacer attachment point, spacer size, spacer chemical structure, heterodimers, GPCR oligomers
Abstract: G protein-coupled receptors (GPCRs) are major drug targets and are organized in dimeric/oligomeric complexes. These dimers may be composed of identical (homodimer) or different (heterodimer) receptors. GPCR dimerization provides new opportunities for drug design. Different strategies have been developed to specifically target GPCR dimers. Bivalent ligands, which are composed of two functional pharmacophores linked by a spacer, are among the most promising strategies. Due to the constitutive nature of GPCR dimers, bivalent ligands are expected in most cases to bind to and stabilize preexisting dimers rather then to promote ligand-induced dimerization. Most studies on GPCR dimerization were conducted so far in heterologous expression systems. Due the development of heterodimerspecific tools such as bivalent ligands, dimerization has now been confirmed for an increasing number of receptors in native tissues. In this review, we will discuss general considerations for the design and synthesis of bivalent ligands and present the functional in vitro and in vivo properties of reported bivalent ligands.
Export Options
About this article
Cite this article as:
Berque-Bestel Isabelle, Lezoualc'h Frank and Jockers Ralf, Bivalent Ligands as Specific Pharmacological Tools for G Protein-Coupled Receptor Dimers, Current Drug Discovery Technologies 2008; 5 (4) . https://dx.doi.org/10.2174/157016308786733591
DOI https://dx.doi.org/10.2174/157016308786733591 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Beneficial Effects of Azuki Bean (Vigna angularis) Extract: Anti-Oxidant, Anti-Hypertension, and Treatment for Renal Damage
Current Nutrition & Food Science Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews Insight to the Pathophysiology of Stable Angina Pectoris
Current Pharmaceutical Design Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Protein-mediated Fatty Acid Uptake in the Heart
Current Cardiology Reviews Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry The Missed Tc-99m Radiopharmaceuticals for Cardiac Imaging
Current Radiopharmaceuticals Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)
Current Gene Therapy Access-site Complications of the Transradial Approach: Rare But Still There
Current Cardiology Reviews Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Subject index to volume 3
Current Molecular Medicine Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Vasculogenesis and Angiogenesis Depend on the Developmental Origin in the Arterial Tree
Current Medicinal Chemistry Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design Leukotrienes and Atherosclerosis
Current Drug Targets Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Selectins as Targets in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents